BCM
TECH icon

Bridgeway Capital Management’s Bio-Techne TECH Stock Holding History

Bridgeway Capital Management’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20,200
Closed -$1.65M – 1425
2023
Q2 		$1.65M Hold
20,200
– – 0.04% 602
2023
Q1 		$1.5M Hold
20,200
– – 0.04% 621
2022
Q4 		$1.67M Hold
20,200
– – 0.04% 607
2022
Q3 		$1.43M Buy
+20,200
New +$1.75M 0.04% 644

Other funds holding TECH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bridgeway Capital Management's TECH Position: Q3 2023 in Review

Bridgeway Capital Management sold out of Bio-Techne (TECH) in Q3 2023, closing a stake of 20,200 shares — an estimated $1.65M sold.

Bridgeway Capital Management first reported a position in TECH in Q3 2022 and held it in 4 quarters. The position peaked at $1.67M in Q4 2022. 530 funds tracked by Wall St. Rank hold TECH as of Q3 2023.

  • Bridgeway Capital Management reported no remaining Bio-Techne position as of Q3 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 20,200 Bio-Techne shares in Q3 2023, an estimated $1.65M.
  • Bridgeway Capital Management first reported a position in Bio-Techne in Q3 2022 and held it in 4 quarters.
  • Bridgeway Capital Management's Bio-Techne position peaked at $1.67M in Q4 2022.
  • 530 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.